Atalanta Therapeutics

About Atalanta Therapeutics

Atalanta Therapeutics is dedicated to addressing the urgent global need for interventions to treat neurodegenerative diseases. The company was created based on groundbreaking discoveries in RNA interference, offering a powerful therapeutic approach to halt diseases at their source.

Products & Services

di-siRNA:A unique RNA interference approach aimed at developing innovative medicines for CNS diseases.

RNAi Therapies for CNS Diseases:Investigational therapies targeting conditions like Huntington’s disease and KCNT1-related epilepsy using gene silencing techniques.

Specialties

RNA interference (RNAi) Neurodegenerative disease treatment Gene silencing Central Nervous System (CNS) diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 97000000 MR: - FA: $97 million FAN: 97000000	D: 2025-01-28 FD: 2025-01-28	9 investors

Series B Latest

2025-01-28

$97.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sarah Tabrizi

Director of the UCL Huntington’s Disease Centre

A

Alicia Secor, MBA

President & CEO

A

Aimee L. Jackson, Ph.D.

Chief Scientific Officer

S

Serena Hung, M.D.

Chief Medical Officer

J

Jeff Young

Chief Financial Officer

M

Morgan Molloy

Chief Corporate Development Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News